四氢呋喃-3-乙酸 | 138498-97-2

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 中文名称: 四氢呋喃-3-乙酸
• 中文别名: (四氢呋喃-3-基)乙酸
• 英文名称: 2-(tetrahydrofuran-3-yl)acetic acid
• 英文别名: 2-(oxolan-3-yl)acetic acid
• CAS: 138498-97-2
• 化学式: C₆H₁₀O₃
• 分子量: 130.144
• InChiKey: JSWKBJIKVSXWDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  271.4±13.0 °C(Predicted)
• 密度：
  1.162±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2932190090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (Tetrahydro-furan-3-yl)-acetic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (Tetrahydro-furan-3-yl)-acetic acid
CAS number: 138498-97-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H10O3
Molecular weight: 130.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

四氢呋喃-3-乙酸可作为有机合成中间体和医药中间体，主要应用于实验室研发和化工生产过程。

反应信息

• 作为反应物：
  描述：

  四氢呋喃-3-乙酸 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.75h， 生成 2-(tetrahydrofuran-3-yl)acetyl chloride
  参考文献：
  名称：

  [EN] TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS
  [FR] TRIAZOLOPYRAZINONES UTILISÉES COMME INHIBITEURS DE PDE1

  摘要：

  本发明提供三唑吡嗪酮作为PDE1抑制剂，并将其用作药物，特别用于治疗神经退行性疾病和精神疾病。

  公开号：

  WO2016055618A1
• 作为产物：
  描述：

  (4,5-dihydro-3(2H)-furylidene)acetic acid 在 钯 作用下， 以 乙酸乙酯 为溶剂， 生成 四氢呋喃-3-乙酸
  参考文献：
  名称：

  HIV protease inhibitors useful for the treatment of aids

  摘要：

  形式为A-G-B-B-J的化合物中，其中A是胺保护基或脲，G是用含有碱性胺氮的二肽同分异构体替代，B是氨基酸或其类似物，J是小的末端基团。这些化合物在抑制HIV蛋白酶、预防或治疗HIV感染以及治疗艾滋病方面是有用的，无论是作为化合物、药学上可接受的盐、药用组合成分，还是与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合与否。还描述了治疗艾滋病和预防或治疗HIV感染的方法。

  公开号：

  EP0434365A3

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015180612A1

  公开（公告）日：2015-12-03

  Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

  揭示了新型视黄醇相关孤儿受体γ（RORγ）调节剂及其在通过RORγ介导的疾病治疗中的应用。
• Functionalized 6-(piperidin-1-yl)-8,9-diphenyl purines as inverse agonists of the CB1 receptor – SAR efforts towards selectivity and peripheralization
  作者：George Amato、Robert Wiethe、Amruta Manke、Vineetha Vasukuttan、Rodney Snyder、Scott Runyon、Rangan Maitra

  DOI：10.1016/j.bmc.2019.07.002

  日期：2019.8

  is functionalized with alkyl, heteroalkyl, aryl and heteroaryl groups using a connector in the form of an amine, amide, sulfonamide, sulfamide, carbamate, oxime, amidine, or guanidine. We also report more polar replacements for the 4-chlorophenyl group in the 9-position of the purine core, which improve calculated physical properties of the molecules. These studies resulted in compounds such as 75 that

  1型大麻素受体（CB1）的拮抗剂可用于治疗糖尿病，肝病和纤维化。Otenabant（1）是一种有效且选择性的CB1反向激动剂，目前正在研究中作为抗肥胖药，但一旦已知与另一种市售反向激动剂rimonabant（2）相关的不良反应，其发展就会中止。CB1的非组织选择性拮抗剂具有高水平的脑部渗透性，会对一小部分患者产生不良影响，包括焦虑，抑郁和自杀意念。当前，正在努力生产大脑渗透受限的化合物。在本报告中，探索了新型的1类似物，以开发和测试外围化策略。研究了1的哌啶作为连接基，它被烷基，杂烷基，使用胺，酰胺，磺酰胺，磺酰胺，氨基甲酸酯，肟，am或胍形式的连接基形成芳基和杂芳基。我们还报告了嘌呤核9位中4-氯苯基的更多极性替代物，这改善了分子的计算物理性能。这些研究产生了诸如hCB1的有效反向激动剂之类的化合物，例如75，对hCB1的选择性比hCB2高。SAR研究揭示了调节物理特性以限制大脑暴露的方
• Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists
  作者：George S. Amato、Amruta Manke、Vineetha Vasukuttan、Robert W. Wiethe、Rodney W. Snyder、Scott P. Runyon、Rangan Maitra

  DOI：10.1016/j.bmc.2018.07.043

  日期：2018.8

  Antagonists of peripheral type 1 cannabinoid receptors (CB1) may have utility in the treatment of obesity, liver disease, metabolic syndrome and dyslipidemias. We have targeted analogues of the purine inverse agonist otenabant (1) for this purpose. The non-tissue selective CB1 antagonist rimonabant (2) was approved as a weight-loss agent in Europe but produced centrally mediated adverse effects in

  外周1型大麻素受体（CB1）的拮抗剂可用于治疗肥胖症，肝脏疾病，代谢综合征和血脂异常。为此，我们靶向了嘌呤反向激动剂otenabant（1）的类似物。非组织选择性CB1拮抗剂利莫那班（2）在欧洲被批准为减肥药，但在某些患者中产生了中枢介导的不良反应，包括烦躁不安和自杀意念导致其退出。现在正在努力生产大脑暴露受限的化合物。虽然已经报道了许多关于2的结构-活性关系（SAR）研究以及周边化合物，但1仍然相对较少研究。在本报告中，我们追求的是1的类似物，其中将4-氨基哌啶基团切换为哌嗪基团，以更好地理解SAR，最终生产出脑渗透受限的化合物。为了进入结合口袋并调节物理性质，使用各种连接器，包括酰胺，磺酰胺，氨基甲酸酯和脲，将哌嗪用烷基，杂烷基，芳基和杂芳基官能化。这些研究产生的化合物是hCB1的强效拮抗剂，对hCB1的选择性比hCB2高。获得的SAR导致发现了65（Ki = 4 nM，对hCB1的选择性是hCB2的>
• [EN] NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE<br/>[FR] NOUVEAUX ACTIVATEURS DE LA GUANYLATE CYCLASE SOLUBLE ET LEUR UTILISATION
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016042536A1

  公开（公告）日：2016-03-24

  The invention relates to activators of soluble guanylate cyclase of generic formula (I) and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.

  这项发明涉及通用式(I)的可溶性鸟苷酸环化酶激活剂及其在制药组合物中的应用，主要是局部给药的眼科组合物。这些制药组合物对于降低哺乳动物种类的动物眼内压是有用的。
• [EN] COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION DESDITS COMPOSÉS
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2018098499A1

  公开（公告）日：2018-05-31

  The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

  本发明部分涉及融合的杂环化合物和组合物，用于预防和/或治疗与电压门控钠离子通道异常功能相关的疾病或症状，例如异常的晚期/持续性钠电流。本文还提供了治疗与钠离子通道异常功能相关的疾病或症状，包括德拉维特综合征或癫痫的方法。